Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK-1 plus 5-HT3 inhibitor combination for prevention of nausea and vomiting during multi-week platinum chemotherapy
ChiCTR2600134502Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fosrolapitant, palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Complete response. Started Oct 2025; status: recruiting.
02
Drugs
fosrolapitantpalonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2600134502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134502.